17 unknown, 13 completed, 6 not yet recruiting, 3 active not recruiting. 41 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 41 | Unknown 17, Completed 13, Not yet recruiting 6, Active not recruiting 3, Recruiting 2 |
Follow Cisplatin: new trials by email Literature Review of Cisplatin trials Research Report on Cisplatin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial of Pembrolizumab With Chemotherapy or Chemoradiotherapy in Participants From India With Different Types of Cancer (MK-3475-G44/KEYNOTE-G44) Pembrolizumab, Cisplatin, 5-Fluorouracil - Neoplasm Malignant, Gastric Neoplasms | Phase 4 | Not yet recruiting | Merck Sharp & Dohme LLC | 150 | 2026-11-06 | 2026-09-03 |
| A Prospective, Multi-Center, Phase 4, Single Arm Study To Assess The Safety and Tolerability of Perioperative Durvalumab in Combination With Neoadjuvant Gemcitabine Plus Cisplatin in Indian Patients With Muscle-Invasive Bladder Cancer Cle-Invasive Durvalumab, Gemcitabine, Cisplatin - Muscle-Invasive Bladder Cancer (MIBC) | Phase 4 | Not yet recruiting | AstraZeneca | 50 | 2026-10-20 | 2026-10-15 |
| A Single-arm, Multicenter Clinical Study of Iparomlimab and Toripalimab in Combination With Bevacizumab and Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer Iparomlimab and Toripalimab, Bevacizumab, Gemcitabine (1000 mg/m2) - Biliary Tract Cancer (BTC) | Phase 4 | Recruiting | Xianglin Yuan | 32 | 2026-06-10 | 2026-09-15 |
| Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction Liposome Irinotecan, Platinum, Tislelizumab - Small Cell Lung Cancer | Phase 4 | Not yet recruiting | China Medical University, China | 31 | 2025-04-30 | 2025-04-30 |
| Benmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer Benmelstobart, Anlotinib, Carboplatin or cisplatin - Extensive-stage Small Cell Lung Cancer | Phase 4 | Not yet recruiting | Peking Union Medical College Hospital | 50 | 2025-04-15 | 2025-04-23 |
| A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer Toripalimab, Cisplatin, Gemcitabine - Nasopharyngeal Cancer Recurrent | Phase 4 | Recruiting | Coherus Oncology, Inc. | 100 | 2024-11-01 | 2026-07-30 |
| Irinotecan Liposomes for the Treatment of Neuroendocrine Carcinoma Irinotecan liposomes combined with cisplatin/carboplatin - Neuroendocrine Tumors | Phase 4 | Not yet recruiting | First Affiliated Hospital Xi'an Jiaotong University | 20 | 2024-07-01 | 2024-07-03 |
| Serplulimab Combined With Nab-paclitaxel and Cisplatin in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma Serplulimab Combined With Nab-paclitaxel and Cisplatin, nab-paclitaxel，Cisplatin - Esophageal Squamous Cell Carcinoma | Phase 4 | Not yet recruiting | Yang Jianjun, PhD | 80 | 2024-05-01 | 2024-04-29 |
| Preoperative Neoadjuvant Immunotherapy Combined With Chemotherapy for Stage Ⅲ Unresectable Non-small Cell Lung Cancer Tislelizumab, Pemetrexed (Non-squamous NSCLC) or Nab-paclitaxel(Squamous NSCLC), Carboplatin or Cisplatin - Non-small-cell Lung Cancer (NSCLC) | Phase 4 | Unknown | The Affiliated Hospital of Qingdao University | 30 | 2024-01-18 | 2024-04-10 |
| Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma Atezolizumab, Nab paclitaxel, Carboplatin - Non-Small Cell Lung Cancer Metastatic | Phase 4 | Active not recruiting | Nikolaj Frost MD | 136 | 2023-12-06 | 2026-03-10 |
| Correlation Between Myocardial Injury and Intestinal Flora Changes Associated With Oncology Drug Therapy and the Preventive of Probiotics Bifidobacterium Bifidum Oral Capsule, Cisplatin, Carboplatin - Cancer Therapy-related Cardiovascular Toxicity | Phase 4 | Unknown | Peking University Third Hospital | 200 | 2023-02-15 | 2023-02-16 |
| Tislelizumab With Chemotherapy or Radiation for Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma (TINES) Tislelizumab + cisplatin + paclitaxel, Tislelizumab + radiotherapy - Esophageal Squamous Cell Carcinoma | Phase 4 | Unknown | First Affiliated Hospital Xi'an Jiaotong University | 32 | 2022-10-10 | 2023-06-29 |
| A Prospective, Single-arm Clinical Study of Pabrolizumab in Combination With Cisplatin + 5-FU for the Neoadjuvant Treatment of Unresectable, Advanced Squamous Carcinoma of the Temporal Bone Single-arm Clinical Study Paprizumab combined with cisplatin and 5-FU - Temporal Bone Squamous Cell Carcinoma | Phase 4 | Unknown | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 30 | 2022-06-01 | 2022-07-06 |
| A Prospective Clinical Study of Ruxolitinib and Etoposide Combined With DDGP Regimen (RUE-DDGP) in Induction Therapy of T/NK Cell Lymphoma-associated Hemophagocytic Syndrome. Ruxolitinib, Etoposide, Dexamethasone, Gemcitabine, Pegaspargase, cis-platinum - Hemophagocytic Syndrome, T/NK-Cell Lymphoma | Phase 4 | Unknown | Zhengzhou University | 30 | 2021-05-30 | 2021-08-11 |
| A Trial of Nimotuzumab and Pinkiller Efficacy and Pain in Advanced Head and Neck Squamous Cell Carcinoma Nimotuzumab, cis-platinum, IMRT combine with cisplatin concurrent chemotherapy - Head and Neck Cancer | Phase 4 | Active not recruiting | Biotech Pharmaceutical Co., Ltd. | 171 | 2021-05-15 | 2025-03-17 |
| PAXG Out in the Country PAXG regimen (cisplatin, nab-paclitaxel, capecitabine, gemcitabine) chemotherapy - Pancreatic Ductal Adenocarcinoma | Phase 4 | Unknown | IRCCS San Raffaele | 175 | 2020-07-08 | 2021-02-10 |
| Lobaplation or Cisplatin in Adjuvant Chemotherapy for Esophageal Carcinoma Lobaplatin, Cisplatin - Esophageal Cancer | Phase 4 | Completed | Henan Cancer Hospital | 733 | 2018-01-31 | 2020-08-28 |
| Combination Chemotherapy Including Cisplatin, Ifosfamide, Gemcitabine, L-asparaginase, Etoposide and Dexamethasone as Treatment of Newly Diagnosed and Relapsed/Refractory Peripheral T Cell Lymphomas cisplatin, ifosfamide, gemcitabine - Peripheral T Cell Lymphoma | Phase 4 | Unknown | The University of Hong Kong | 50 | 2017-02-24 | 2018-06-11 |
| Clarify of Predictive Risk Factors of Chemotherapy-induced Liver Injury docetaxel and cisplatin - Liver Injury, Drug-Induced | Phase 4 | Unknown | Second Affiliated Hospital of Nanchang University | 120 | 2017-02-10 | 2017-03-03 |
| Outcome of Cisplatin and Vinblastine Versus Paclitaxel and Carboplatin as Sequential Chemotherapy Followed by Radiotherapy in Locally Advanced Non-small Cell Lung Cancer Paclitaxel, Carboplatin, Cisplatin - Carcinoma, Non-Small-Cell Lung | Phase 4 | Completed | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | 60 | 2017-01-01 | 2019-03-08 |
Showing 20 of 41. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (8) · Head and Neck Neoplasms (3) · Small Cell Lung Carcinoma (3) · Esophageal Neoplasms (2) · Esophageal Squamous Cell Carcinoma (2) · Lymphoma, Extranodal NK-T-Cell (2) · Uterine Cervical Neoplasms (2) · Adenocarcinoma of Lung (1) · Anemia (1) · Biliary Tract Neoplasms (1) · Carcinoma, Squamous Cell (1) · Chemical and Drug Induced Liver Injury (1) · Lung Neoplasms (1) · Lymphohistiocytosis, Hemophagocytic (1) · Lymphoma, Mantle-Cell (1)
First Affiliated Hospital Xi'an Jiaotong University (2) · Nanjing NingQi Medicine Science and Technology Co., Ltd. (2) · AGO Study Group (1) · Anhui Provincial Hospital (1) · Assistance Publique Hopitaux De Marseille (1) · AstraZeneca (1) · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh (1) · Biotech Pharmaceutical Co., Ltd. (1) · Centre Oscar Lambret (1) · China Medical University, China (1) · Chinese Academy of Medical Sciences (1) · Coherus Oncology, Inc. (1) · Dermatologic Cooperative Oncology Group (1) · Fundacion Clinic per a la Recerca Biomédica (1) · Guangdong Association of Clinical Trials (1)
China (22) · Germany (4) · Canada (2) · France (2) · United States (2) · Bangladesh (1) · Hong Kong (1) · Italy (1) · New Zealand (1) · Spain (1) · Taiwan (1) · Turkey (Türkiye) (1)
Axel Hauschild, MD (1) · Binghe Xu, M.D. (1) · Edibe Taylan, MD (1) · EnXiao Li, PhD (1) · Gabriele Calaminus, MD (1) · Girish Dhall, MD (1) · Heinz Koelbl, MD (1) · Jens Ulrich, MD (1) · Jonathan Finlay, MD (1) · Junke Fu (1) · Lejie Cao, professor (1)
PMID 27566586, PMID 30017831, PMID 31200823, PMID 33034052, PMID 33633029, PMID 34589419, PMID 34699693
2009 (1), 2014 (1)